Georgetown University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Georgetown University sits in the top decile of US sponsors by registered trial count (#144 of 15,742 sponsors by registered trial count).

227 total trials 34 currently recruiting 130 completed early-phase tilt top decile by trial count

Georgetown University: 227 sponsored US clinical trials, 34 recruiting.

Georgetown University sponsors 227 registered US clinical trials on ClinicalTrials.gov, 34 of them currently recruiting, and 130 completed. 27 of these trials are in Phase 3-4 (later-stage) and 98 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 5 trials.

Top-decile sponsor footprint

Georgetown University ranks in the top decile of sponsors by registered trial count (#144 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 26/100

130 of 174 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (74.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

227 total, page 3 of 5

COMPLETED NA

Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer

NCT03075540
COMPLETED

START & STOPP in GWI

NCT03560830
TERMINATED Phase 2

Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer

NCT02654639
COMPLETED

Patient Self Monitoring to Evaluate 30 Day Post Discharge Heart Failure Outcomes

NCT02527759
COMPLETED NA

Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility

NCT02133703
COMPLETED NA

Pediatric Health Promotion Program

NCT03322501
COMPLETED

The Effects of Water Temperature on the Cold Pressor Test

NCT03083626
TERMINATED Phase 2

A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer

NCT02402036
TERMINATED NA

Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach

NCT02358863
TERMINATED Phase 1

CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)

NCT02365714
COMPLETED Phase 1

Phase I Study of Intravenous Artesunate for Solid Tumors

NCT02353026
COMPLETED Phase 1

Nilotinib in Cognitively Impaired Parkinson Disease Patients 001

NCT02281474
COMPLETED NA

Effects of Reading to Preterm Infants on Baby and Parents' Well Being

NCT02518997
TERMINATED Phase 1

A Phase I/II Study of Ganetespib in Combination With Doxorubicin

NCT02261805
COMPLETED NA

Effect of Cigarette Pack Warnings and Packaging Among Young Adult Smokers

NCT03446170
COMPLETED NA

An Exercise Intervention for Prostate Cancer Patients Receiving Androgen Deprivation Therapy

NCT02248350
TERMINATED Phase 2

Study of Gemcitabine and Abraxane for Pancreas Cancer

NCT02242409
COMPLETED NA

A Cognitive Behavioral Therapy and Yoga Program for Trauma Symptoms

NCT02368444
COMPLETED Phase 4

Myobloc Atrophy Study

NCT02052024
TERMINATED Phase 1

A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors

NCT01871311
COMPLETED NA

Non-Invasive Evaluation of Transplant Kidney Using OCT

NCT02084966
TERMINATED Phase 1

Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

NCT02200848
COMPLETED Phase 3

Lombardi Comprehensive Cancer Center/Legacy Pilot Study to Reduce Adverse Smoking Outcomes in the Context of Lung Cancer Screening

NCT02267096
TERMINATED Phase 4

Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers

NCT02015910
COMPLETED Phase 1

Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and Mood

NCT02104401
TERMINATED Phase 2

Maintenance Dovitinib for Colorectal and Pancreas Cancer

NCT01888965
COMPLETED Phase 4

Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation

NCT01939145
COMPLETED NA

Exercise Intervention Metabolic Syndrome Prostate Cancer Black Men

NCT02379559
COMPLETED NA

Effects of a Structured Exercise Program on Cancer-Related Fatigue in Women Receiving Radiation Therapy for Breast Cancer

NCT02117011
COMPLETED

Rapid Strep Testing in Children With Recent Streptococcal Pharyngitis

NCT03055728
COMPLETED NA

Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers

NCT02222337
COMPLETED NA

Pilot Study to Determine Percent Tissue Perfusion and Cellular Viability Using SPY Imaging

NCT01522495
COMPLETED NA

Quit and Fit: A Tobacco Cessation and Energy Balance Pilot for African Americans

NCT02103582
TERMINATED Phase 2

The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma

NCT01813214
TERMINATED Phase 2

Increased Sensitivity to Pain Caused by Opioids in People Who Have Abused Prescription Opioids

NCT01821430
COMPLETED Phase 1

Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children

NCT01652287
COMPLETED NA

Using Transcranial Direct Current Stimulation (tDCS) to Improve Post-Stroke Aphasia

NCT01709383
COMPLETED Phase 2

Molecularly Tailored Therapy for Pancreas Cancer

NCT01888978
COMPLETED Phase 2

Exergaming Intervention and Breast Cancer Biomarkers in Black Women

NCT02152462
TERMINATED NA

Lumbar Punctures in Neonates: Improving Success Rates and Minimizing Pain

NCT01606150
COMPLETED

Reader Study to Demonstrate That Use of ClearRead Confirm is Superior to the Use Standard AP/PA X-ray Image

NCT01655329
TERMINATED NA

ActiV.A.C.+ Compression Therapy Versus Compression Therapy Alone for the Treatment of Chronic Venous Ulcerations

NCT01528293
TERMINATED NA

Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

NCT01790516
TERMINATED Phase 1

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

NCT01484041
COMPLETED Phase 1

A Study of the Effects of PEITC on Oral Cells With Mutant p53

NCT01790204
COMPLETED Phase 4

A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy

NCT01497652
TERMINATED Phase 1

Phase I Study of CS-7017 and Bexarotene

NCT01504490
TERMINATED Phase 1

Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

NCT01504477
COMPLETED NA

Rehabilitation and Prophylaxis of Anomia in Primary Progressive Aphasia

NCT02675270
COMPLETED Phase 1

Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV

NCT01570595
← Previous Page 3 of 5 Next →

Phase Distribution

PhaseTrial count
Phase 1 43
Phase 2 55
Phase 3 16
Phase 4 11

Therapeutic Areas

Breast Cancer 5
Stroke 4
Agoraphobia 3
Hereditary Breast and Ovarian Cancer 3
Social Anxiety Disorder 3
Panic Disorder 3
Generalized Anxiety Disorder 3
Anxiety Disorders 3
Pancreatic Cancer 3
Lung Cancer 3

What is open in the Georgetown University pipeline

34 recruiting of 227 indexed (15% open); 130 completed (57%).

Phase mix: 27 late (III/IV) vs 98 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (5 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Georgetown University: open-pipeline peers nationwide

Peers matched on 227 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Georgetown University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200250 5%10%15%20% Total trials Recruiting share Georgetown UniversityUniversity of IowaUniversity Hospitals Cleveland Medical CenterBrown UniversityNational Eye Institute (NEI)Arizona State University59th Medical WingAlliance Foundation TrialsHoag Memorial Hospital Presbyterian
Georgetown University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Georgetown University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 227 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Georgetown University page

227 registered trials is a research-attention snapshot, not an endorsement of Georgetown University or any single study.

  • 34 of Georgetown University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Georgetown University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Georgetown University pipeline card: 227 registered trials from official public datasets.Report a data error.